Unmet needs in CRC: Survey results offer hope



A colorectal cancer diagnosis can change your life in countless ways — physically, emotionally, and socially. At the Colorectal Cancer Alliance, we’re dedicated to listening to patients and survivors so we can offer the meaningful support they need. Recently, we launched a survey to better understand the biggest unmet needs facing the colorectal cancer (CRC) community. Our findings were presented at the ASCO Gastrointestinal Cancers Symposium last week.
What We Found
Why It Matters
These findings shed light on the depth of psychosocial and physical needs faced by CRC patients and survivors. We now have tangible data showing that life after diagnosis can be isolating and that support is needed far beyond the doctor’s office.
Armed with these insights, the Alliance is committed to creating new support programs, resources, and clinical strategies to better serve our community. Whether it’s connecting you to a Buddy through our peer support program or offering guidance through treatment and beyond, we want to ensure no one faces colorectal cancer alone.
“We believe these survey results will spark meaningful changes in CRC care and provide renewed hope,” said Kim Newcomer, an Alliance staff member who presented posters at ASCO GI. “If you’re a part of our community, thank you. Your voice helps shape the future of support and care for everyone impacted by CRC.”

hrough Project Cure CRC, the Alliance is fueling bold, early-stage research with the potential to transform colorectal cancer treatment. Dr. Lisa Mielke’s groundbreaking work explores how the gut’s immune system and nerve signaling influence cancer growth—opening the door to new therapeutic approaches, including repurposed existing drugs. This is what’s possible when promising ideas get the support they need to move forward.

Biomarker testing can guide colorectal cancer treatment and improve outcomes. Learn how CLEAR for CRC is helping patients access this critical tool.

Meet Project Cure CRC researcher Kevin Van der Jeught, whose mRNA-based immunotherapy research aims to unlock new treatments for colorectal cancer patients.